Keytruda (Pembrolizumab Injection) product leaflet with dosage, administration, indications and safety information.
This leaflet provides essential information for the use of Keytruda (Pembrolizumab Injection), including its composition, dosage form, approved indications and recommended dosing regimens. It also details preparation instructions, storage conditions, and safety precautions for healthcare professionals.
Keytruda is supplied as a 100 mg/4 ml sterile solution for intravenous infusion. The document outlines specific dosing for melanoma (2 mg/kg) and a fixed 200 mg dose for non‑small cell lung cancer, esophageal cancer and head‑and‑neck squamous cell carcinoma, along with guidance on infusion duration and handling of the product. This manual is written in Chinese.
| Dosage form | 100 mg/4 ml injection |
|---|---|
| Recommended dose for melanoma | 2 mg/kg |
| Recommended dose for NSCLC, esophageal and head‑neck cancers | 200 mg fixed dose |
| Administration route | Intravenous infusion over ≥30 minutes |
Keytruda is supplied as a 100 mg/4 ml sterile injection solution.
It must be given by intravenous infusion lasting at least 30 minutes.
Do not shake the vial, bring it to room temperature (≤25 °C), then dilute with 0.9 % saline or 5 % glucose to a final concentration of 1–10 mg/ml.